Magnetic instrument for the homing of therapeutic cells and the elimination of excess therapeutic cells

1. A method for magnetic attraction of therapeutic cells comprising:

a. selecting therapeutic cells.

b. labeling of the cells with magnetic particles to produce therapeutic labeled cells,

c. introducing the therapeutic labeled cells according to b. into a body,

d. introducing a device into the body wherein the device comprises:

i. a guide element comprising a spring elastic distal area and a proximal area,

ii. a magnetic function element which is introduced between the distal area and the proximal area of the guide element, and

iii. a stabilizing element which is connected to the proximal area of the guide element and

e. magnetically attracting and binding of the labeled therapeutic cells by the magnetic element of the device.

2. The method according to claim 1 , wherein the therapeutic cells are magnetically attracted in a blood vessel system, efferent glandular ducts of the pancreatic gland, lacrimal gland, parotid gland, efferent glandular ducts of the mucous glands, mixed glands, skin and appendage glands, mammary glands, spinal canal, cerebral ventricle system, peridural space, gallbladder and its efferent anatomical structures, efferent urinary tract or a lymphatic system, body cavities of an abdomen, chest, uterus, urogenital apparatus or a joint or gastrointestinal tract.

3. The method of claim 1 , wherein said method is configured for endoscopic administration, wherein the device further comprises:

iv. an adapter and

v. a longitudinally movable sleeve, wherein the magnetic function element comprises one or more magnetic elements having detection molecules, and

endoscopically administering the therapeutic cells and magnetically attracting them via said one or more magnetic elements.

4. The method of claim 1 , wherein the device is introduced into a vascular system via a vascular access.

5. The method of claim 1 , wherein the therapeutic cells are magnetically attracted in course of a interventional treatment of disease selected from the group consisting of congenital diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, infectious diseases, hormonal diseases, diseases of blood and hematopoietic organs, diseases of the digestive tract, liver, the gallbladder, pancreatic gland, diseases of the urogenital tract and the kidneys, diseases of the heart, pathological changes in the blood vessel system and the lymphatic system, diseases of lungs, diseases of the central or peripheral nervous system and neurodegenerative diseases.

6. The method of claim 5 , wherein the congenital diseases are selected from the group consisting of an autosomally recessive disease, an autosomally dominant disease, a gonosomal and mitochondrial and/or extrachromosomal disease or a disease that can be attributed to a genetic predisposition.

7. The method of claim 5 , wherein the proliferative diseases are selected from the group consisting of a tumor, a precancerous condition, a dysplasia, a neuroendocrine tumor, an endometriosis and a metaplasia.

8. The method of claim 5 , wherein the autoimmune diseases are selected from the group consisting of rheumatoid arthritis, inflammatory intestinal disease, osteoarthritis, neuropathic pain, alopecia areata, psoriasis, psoriatic arthritis, acute pancreatitis, allograft rejection, allergies, allergic inflammations of the lungs, multiple sclerosis, Alzheimer's disease, Crohn's disease and systemic lupus erythematosus.

9. The method of claim 5 , wherein the infectious diseases are selected from the group consisting of a parasitic disease, a bacterial disease and a viral disease.

10. The method of claim 5 , wherein the hormonal diseases are selected from the group consisting of a disease relating to sugar metabolism, fat metabolism, protein metabolism, sexual development and reproduction, water-salt balance, growth and cell production.